Identification of predictive parameters for 6-MP response in AML patients

• Conditions: treatment; 10024324; AML

• Registration Number: NL-OMON31997
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

- age >18 years
- diagnosed with (relapsing) AML not eligible for intensive chemotherapy

Exclusion Criteria

Ineligible to perform proposed test

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- AML blasts cells will be analyzed for the expression of drug-resistant<br /><br>parameters, nuclear receptor and the in vitro responsiveness to 6-MP.<br /><br>- Facs analyses will be performed to define the changes in lymphoid markers<br /><br>during treatment of 6-MP.<br /><br>- Treatment response of patients will be defined by improvements in peripheral<br /><br>blood cell counts and bone marrow composition.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>